Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430660 · ClinicalTrials.gov registry record · NA
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients
A NA study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT04430660 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 8 participants.
The verdict
NCT04430660, a NA study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
A recent pilot study, GLIMPSE (NCT02690168), was recently completed which demonstrated that the rate of glial acetate metabolism (GAM) is closely associated with susceptibility to fasting-induced hypoglycemia in healthy adults. Insulin-induced hypoglycemia is a common complication of diabetes treatment and is a major barrier to the maintenance of healthy glucose levels in individuals with diabetes. The primary purpose of the study is to test the proof-of-concept that there is an association between the rate of GAM and susceptibility to insulin-induced hypoglycemia. In order to observe such a relationship the rate of GAM will be measured in a patient population known to frequently experience hypoglycemia, i.e., individuals with type 1 diabetes mellitus (T1DM).
Interventions
- OTHER 13C-MRS procedure/Acetate infusion
- DEVICE Continuous glucose monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2022-05-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04430660
The ClinicalTrials.gov registry entry for NCT04430660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13C-MRS procedure/Acetate infusion is the first listed.
NCT04430660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04430660 about?
NCT04430660 is a clinical study titled "Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients". A recent pilot study, GLIMPSE (NCT02690168), was recently completed which demonstrated that the rate of glial acetate metabolism (GAM) is closely associated with susceptibility to fasting-induced hypoglycemia in healthy adults. Insulin-induced hypoglycemia is a common complication of diabetes treatm...
What is the current status of trial NCT04430660?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2020-08-19. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04430660?
The interventions under investigation include: 13C-MRS procedure/Acetate infusion (OTHER), Continuous glucose monitoring (DEVICE).
Who is sponsoring clinical trial NCT04430660?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.